Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease

Company Overview - Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with significant unmet medical needs [1] - The company has a pipeline of immune-modulating assets, including ARCALYST®, abiprubart, and mavrilimumab, targeting underserved cardiovascular and autoimmune conditions [1] Abiprubart Development - Abiprubart is an investigational humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, which is critical for B-cell maturation and immune responses [4] - The Phase 2b clinical trial of abiprubart in Sjögren's Disease has commenced, with enrollment of approximately 201 patients randomized to receive either abiprubart or placebo over 24 weeks [6][8] - The primary endpoint of the trial is the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) versus placebo at Week 24 [6] Financial Outlook - Kiniksa expects to remain cash flow positive on an annual basis while fully funding the clinical development of abiprubart in Sjögren's Disease [9]